ADVANZ PHARMA and Enzene enter an exclusive partnership for biosimilar development and commercialisation

London, UK and Pune, INDIA – 27/08/2024: – ADVANZ PHARMA Holdco Limited (“ADVANZ PHARMA” or “the Company”), a UK headquartered global pharmaceutical company with a strategic focus on speciality, hospital and rare disease medicines in Europe, Canada, and Australia and Enzene Biosciences, a biopharmaceutical company specialising in the development and manufacturing of biosimilars, today announced a strategic partnership for the commercialisation of a proposed biosimilar for a rare disease indication. This partnership marks another important milestone in ADVANZ PHARMA’s commitment to expand access to high-quality biosimilar medicines.

Enzene’s biologic development and manufacturing expertise will be complemented by ADVANZ PHARMA’s market access and commercialisation capabilities in Europe.

Susanna El-Armale, Chief Corporate Development Officer at ADVANZ PHARMA, said: “This partnership underscores our commitment to bring impactful therapies to market. By leveraging Enzene’s development capabilities, we aim to improve access to a valuable treatment option, reinforcing our position as a partner of choice for commercialisation of specialty and rare disease medicines in Europe.”

Himanshu Gadgil, CEO of Enzene Biosciences, remarked, “Through strategic investments in advanced development and manufacturing capabilities, we have successfully lowered the cost of producing biosimilars, advancing our goal of delivering affordable healthcare to those with debilitating illnesses. Our partnership with Advanz Pharma aligns perfectly with this goal. Their extensive expertise in market access and commercialization, combined with a commitment to addressing unmet needs in rare disease treatments, positions us to significantly enhance the availability of affordable, life-saving therapies across Europe and beyond.”

About ADVANZ PHARMA

Partner of choice in specialty, hospital, and rare disease medicines

ADVANZ PHARMA is a global pharmaceutical company with the purpose to improve patients’ lives by providing and enhancing the specialty, hospital, and rare disease medicines they depend on. Our headquarters are in London, UK. We have commercial sales in more than 90 countries globally and have a direct commercial presence in more than 20 countries, including key countries in Europe, the US, Canada, and Australia, a Centre of Excellence in Mumbai, India, as well as an established global distribution and commercialisation partner network. ADVANZ PHARMA’s product portfolio and pipeline comprises innovative medicines, specialty generics & biosimilars, and originator brands. Our products cover a broad range of therapeutic areas, including hepatology, gastroenterology, anti-infectives, critical care, endocrinology, oncology, CNS, and, more broadly, rare disease medicines. Our ambition is to be a partner of choice for the commercialisation of specialty, hospital, and rare disease medicines in Europe, Canada, and Australia. In line with our ambition, we are partnering with biopharma and development companies to bring medicines to patients. We can only achieve this due to our dedicated and highly qualified employees, acting in line with our company values of entrepreneurship, speed, and integrity.

For more information, please visit their website or LinkedIn.

For media inquiries, please contact:

Courtney Baines

ADVANZ PHARMA

Tel: +44 7776 516979 Email: courtney.baines@advanzpharma.com

About Enzene Biosciences Ltd

Enzene is an innovation-driven biotech company and a subsidiary of Alkem Laboratories Ltd (one of the top five pharmaceutical companies in India), located in Pune, India, Enzene’s focus lies in producing biosimilars, novel biologics, synthetic peptides, and phytopharmaceuticals. Enzene also offers a range of CDMO and CMO services in biologics. For more information on Alkem Laboratories Ltd, please visit www.alkemlabs.com.